Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A Comprehensive Review on PLGA-Based Nanoparticles used for Rheumatoid Arthritis


Affiliations
1 School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India
     

   Subscribe/Renew Journal


Worldwide, Nanotechnology is frequently used for various applications in fields of medical science and therapeutics. However, biodegradable nanoparticles can improve the therapeutic value of various H2O soluble / insoluble drugs by improving solubility, bioavailability, retention time and protection of premature degradation of drugs in biological environment. In comparison to general Nanoparticles (NPs), encapsulation process with polymeric NPs are considered to be more fruitful and advanced as it provides better patient compliance. Since three decades through extensive research, polymers were first introduced as biodegradable or naturally dissolved surgical device. Current scenario utilizes polymeric based nanoparticles for the treatment of various ailments. Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease related to joints which hampers the normal life by exhibiting extra-articular manifestations. In-spite of major advances in drug therapies, still limitations are pervading with severe side effects in case of conventional drug delivery systems. Although different polymers are used for the preparation of Nanoparticles, utilization of USFDA and EMA approved Poly (lactic-co-glycolic acid) (PLGA) has gained much more popularity due to its unique features like low cytotoxicity, biocompatibility, biodegradability, targeted drug delivery, possibility of sustained release formulation and long biomedical applications. Nevertheless, researchers reveled that for targeted drug delivery, key factor involved is the persistance of NPs in systemic circulation of body. However, conventional NPs are rapidly opsonized and cleared through macrophages (fixed MPS) which is considered as foremost challenge in preparing these type of formulations. Hence, in order to overcome these problems, surface modification of conventional NPs with different molecules are needed so as to increase the circulation time and persistance of NPs in the blood. Furthermore, this review explores various key design parameters of RA targeted PLGA- based nanotechnology strategies in improving the treatment of rheumatoid arthritis. It comprehensively addresses various issues related to PLGA-based nanoparticles along with its method of preparation, surface modification and characterization techniques. Unlike usual drugs, nanoparticle drug delivery system aims at providing better patient compliance by delivering the drug to inflamed synovium by reducing systemic side effects.

Keywords

Rheumatoid Arthritis, PLGA Poly (Lactic-Co-Glycolic Acid), Nanoparticles, Adjuvant Induced Arthritis (AIA).
Subscription Login to verify subscription
User
Notifications
Font Size


  • Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. JPS. 2004; 96(3): 229-245.

  • Ferrero‐Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin‐1β generation. Clinical and Experimental Immunology. 2007; 147(2): 227-235.

  • Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-κB and upregulation of TRAIL receptors. Cancer Res. 2009; 69(23): 8958-8966.

  • Schurgers E, Billiau A, Matthys P. Collagen-induced arthritis as an animal model for rheumatoid arthritis: focus on interferon-γ. J Inter Cytok Res. 2011; 31(12): 917-926.

  • Mitragotri S, Yoo JW. Designing micro-and nano-particles for treating rheumatoid arthritis. Arch Pharmacal Res. 2011; 34(11): 1887-1897.

  • Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Current Opinion in Solid State and Materials Science. 2002; 6(4): 319-327.

  • Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. ISMRM. 2007; 25(4): 667-680.

  • Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and surfaces B: Biointerfaces. 2010; 75(1): 1-8.

  • Hussein MS, Zaytoun HA, Elshora OA, Elsabagh HM. Serum Level of Interleukin 34 in Rheumatoid Arthritis Patients: Relation to Disease Activity and Joint Destruction. Tanta Medical Sciences Journal. 2014; 9(3): 62-71.

  • Chiong HS, Yong YK, Ahmad Z, Sulaiman MR, Zakaria ZA, Yuen KH, Hakim MN. Cytoprotective and enhanced anti-inflammatory activities of liposomal piroxicam formulation in lipopolysaccharide-stimulated RAW 264.7 macrophages. Int J Nanomedicine. 2013; 8: 1245.

  • Heo R, Park JS, Jang HJ, Kim SH, Shin JM, Suh YD, Jeong JH, Jo DG, Park JH. Hyaluronan nanoparticles bearing γ-secretase inhibitor: in vivo therapeutic effects on rheumatoid arthritis. JCR. 2014; 192: 295-300.

  • Hofkens W, Grevers LC, Walgreen B, de Vries TJ, Leenen PJ, Everts V, Storm G, van den Berg WB, van Lent PL. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. JCR. 2011; 152(3): 363-369.

  • Koning GA, Schiffelers RM, Wauben MH, Kok RJ, Mastrobattista E, Molema G, ten Hagen TL, Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis. Arthritis and Rheumatism. 2006; 54(4): 1198-1208.

  • Komano Y, Yagi N, Onoue I, Kaneko K, Miyasaka N, Nanki T. Arthritic joint-targeting small interfering RNA-encapsulated liposome: implication for treatment strategy for rheumatoid arthritis.JPET. 2012; 340(1): 109-113.

  • Zhou HF, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, Pham CT. Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials. 2012; 33(33): 8632-8640.

  • Koo OM, Rubinstein I, Onyuksel H. Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis. Pharmaceutical research. 2011; 28(4): 776-787.

  • Chuan YP, Zeng BY, O’Sullivan B, Thomas R, Middelberg AP. Co-delivery of antigen and a lipophilic anti-inflammatory drug to cells via a tailorable nanocarrier emulsion. Journal of colloid and interface science. 2012; 368(1): 616-624.

  • Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. The Journal of rheumatology. 2010; 37(4): 692-703.

  • Mello SB, Tavares ER, Bulgarelli A, Bonfa E, Maranhao RC. Intra-articular methotrexate associated to lipid nanoemulsions: anti-inflammatory effect upon antigen-induced arthritis. Int J Nanomedicine. 2013; 8: 443.

  • Wilson DR, Zhang N, Silvers AL, Forstner MB, Bader RA. Synthesis and evaluation of cyclosporine A-loaded polysialic acid–polycaprolactone micelles for rheumatoid arthritis. European Journal of Pharmaceutical Sciences. 2014; 51: 146-156.

  • Satya Prasad M, Padmaja phaniNV, Nadiya Sk, Masthani Sk, Krishna Satya A. A Review on Role of Nanoparticles in Rheumatoid arthritis therapy, Department of Biotechnology, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur, Andhra Pradesh, India. IJRPB. 2016; 4(6): 2320-3471.

  • Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976; 263(5580): 797.

  • Jain RA. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000; 21(23): 2475-2490.

  • Mao S, Xu J, Cai C, Germershaus O, Schaper A, Kissel T. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. International Journal of Pharmaceutics. 2007; 334(1-2): 137-148.

  • Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2009; 2(2): 219-232.

  • Liu M, Zhou Z, Wang X, Xu J, Yang K, Cui Q, Chen X, Cao M, Weng J, Zhang Q. Formation of poly (L, D-lactide) spheres with controlled size by direct dialysis. Polymer. 2007; 48(19): 5767-5779.

  • Nie H, Lee LY, Tong H, Wang CH. PLGA/chitosan composites from a combination of spray drying and supercritical fluid foaming techniques: new carriers for DNA delivery. JCR. 2008; 129(3): 207-214.

  • Mishima K. Biodegradable particle formation for drug and gene delivery using supercritical fluid and dense gas. Advanced drug delivery reviews. 2008; 60(3): 411-432.

  • Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Progress in polymer science. 2011; 36(7): 887-913.

  • Sharma D. Polymeric nanoparticles preparation techniques and applications for drug delivery system- a brief review, WJPR, 2017; 6(6): 256-282.

  • Choi JS, Seo K, Yoo JW. Recent advances in PLGA particulate systems for drug delivery. J of Pharm Investig. 2012; 42(3): 155-163.

  • Jeong YI, Shim YH, Choi C, Jang MK, Shin GM, Nah JW. Surfactant‐free nanoparticles of poly (DL‐lactide‐co‐glycolide) prepared with poly (L‐lactide)/poly (ethylene glycol). Journal of applied polymer science. 2003; 89(4): 1116-1123.

  • Ameller T, Marsaud V, Legrand P, Gref R, Barratt G, Renoir JM. Polyester-poly (ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties. Pharmaceutical research. 2003; 20(7): 1063-1070.

  • Nam YS, Park JY, Han SH, Chang IS. Intracellular drug delivery using poly (d, l-lactide-co-glycolide) nano-particles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnology letters. 2002; 24(24): 2093-2098.

  • Jain AK, Das M, Swarnakar NK, Jain S. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2011; 28(1): 1-45.

  • Betancourt T, Byrne JD, Sunaryo N, Crowder SW, Kadapakkam M, Patel S, Casciato S, Brannon‐Peppas L. PEGylation strategies for active targeting of PLA/PLGA nanoparticles. Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials. 2009; 91(1): 263-276.

  • Zhang X, Yu C, Sun X, Sun F, Liu J, Li X, Lee RJ, Liu N, Li Y, Teng L. Ketoprofen and MicroRNA-124 Co-loaded poly (lactic-co-glycolic acid) microspheres inhibit progression of Adjuvant-induced arthritis in rats. Int. J. Pharm. 2018; 552(1-2): 148-153.

  • Whitmore SE. Delayed systemic allergic reactions to corticosteroids. Contact Dermatitis. 1995; 32(4): 193-198.

  • Butoescu N, Seemayer CA, Foti M, Jordan O, Doelker E. Dexamethasone-containing PLGA superparamagnetic microparticles as carriers for the local treatment of arthritis. Biomaterials. 2009; 30(9): 1772-1780.

  • Khaled KA, Sarhan HA, Ibrahim MA, Ali AH, Naguib YW. Prednisolone-loaded PLGA microspheres. in vitro characterization and in vivo application in adjuvant-induced arthritis in mice. AAps Pharm Sci Tech. 2010; 11(2): 859-869.

  • Park JS, Yang HN, Jeon SY, Woo DG, Kim MS, Park KH. The use of anti-COX2 siRNA coated onto PLGA nanoparticles loading dexamethasone in the treatment of rheumatoid arthritis. Biomaterials. 2012; 33(33): 8600-8612.

  • Cong Y, Quan C, Liu M, Liu J, Huang G, Tong G, Yin Y, Zhang C, Jiang Q. Alendronate-decorated biodegradable polymeric micelles for potential bone-targeted delivery of vancomycin. Journal of Biomaterials Science, Polymer Edition. 2015; 26(11): 629-643.

  • Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly (lactide)–tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials. 2006; 27(21): 4025-4033.

  • Patel C, Patel M, Patel N, Prajapati PH, Patel CN. Poly Lactic Glycolic Acid (PLGA) As Biodegradable Polymer. Research J. Pharm. and Tech. 2010; 3(2): 354-360.

  • Srivastava S, Patel S, Daharwal S.J., Singh D, Singh M. Rheumatoid Arthritis: An Autoimmune disease prevalent in females. Research J. Pharm. and Tech. 2016; 9(2): 170-172.


Abstract Views: 222

PDF Views: 0




  • A Comprehensive Review on PLGA-Based Nanoparticles used for Rheumatoid Arthritis

Abstract Views: 222  |  PDF Views: 0

Authors

Sangeeta Mohanty
School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India
Sthitapragnya Panda
School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India
Debashis Purohit
School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India
S. I. Sudam Chandra
School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan (Deemed to be University), Bhubaneswar, India

Abstract


Worldwide, Nanotechnology is frequently used for various applications in fields of medical science and therapeutics. However, biodegradable nanoparticles can improve the therapeutic value of various H2O soluble / insoluble drugs by improving solubility, bioavailability, retention time and protection of premature degradation of drugs in biological environment. In comparison to general Nanoparticles (NPs), encapsulation process with polymeric NPs are considered to be more fruitful and advanced as it provides better patient compliance. Since three decades through extensive research, polymers were first introduced as biodegradable or naturally dissolved surgical device. Current scenario utilizes polymeric based nanoparticles for the treatment of various ailments. Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease related to joints which hampers the normal life by exhibiting extra-articular manifestations. In-spite of major advances in drug therapies, still limitations are pervading with severe side effects in case of conventional drug delivery systems. Although different polymers are used for the preparation of Nanoparticles, utilization of USFDA and EMA approved Poly (lactic-co-glycolic acid) (PLGA) has gained much more popularity due to its unique features like low cytotoxicity, biocompatibility, biodegradability, targeted drug delivery, possibility of sustained release formulation and long biomedical applications. Nevertheless, researchers reveled that for targeted drug delivery, key factor involved is the persistance of NPs in systemic circulation of body. However, conventional NPs are rapidly opsonized and cleared through macrophages (fixed MPS) which is considered as foremost challenge in preparing these type of formulations. Hence, in order to overcome these problems, surface modification of conventional NPs with different molecules are needed so as to increase the circulation time and persistance of NPs in the blood. Furthermore, this review explores various key design parameters of RA targeted PLGA- based nanotechnology strategies in improving the treatment of rheumatoid arthritis. It comprehensively addresses various issues related to PLGA-based nanoparticles along with its method of preparation, surface modification and characterization techniques. Unlike usual drugs, nanoparticle drug delivery system aims at providing better patient compliance by delivering the drug to inflamed synovium by reducing systemic side effects.

Keywords


Rheumatoid Arthritis, PLGA Poly (Lactic-Co-Glycolic Acid), Nanoparticles, Adjuvant Induced Arthritis (AIA).

References